Evelyne Silva Brum

Dr. Evelyne Silva Brum

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in British Journal of Pharmacology
Verified
Journal Article
Closed access
EBEvelyne Silva Brum
Evelyne Silva Brum
MFMaria Fernanda Pessano Fialho
Maria Fernanda Pessano Fialho
DADaniel Souza Monteiro de Araújo
Daniel Souza Monteiro de Araújo
LLLorenzo Landini
Lorenzo Landini
MMMatilde Marini
Matilde Marini
SOSara Marchesan Oliveira
Sara Marchesan Oliveira

3 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMaria Fernanda Pessano Fialho
Maria Fernanda Pessano Fialho
EBEvelyne Silva Brum
Evelyne Silva Brum
GBGabriela Becker
Gabriela Becker
IBIndiara Brusco
Indiara Brusco
SOSara Marchesan Oliveira
Sara Marchesan Oliveira
Aromatase inhibitors (AIs) cause symptoms of musculoskeletal pain, and some mechanisms have been proposed to explain them. However, signaling pathways downstream from kinin B2 (B2R) and B1 (B1R) receptor activation and their possible sensitizing of the Transient Receptor Potential Ankyrin 1 (TRPA1) remain unknown. The interaction between the kinin receptor and the TRPA1 channel in male C57BL/6 mice treated with anastrozole (an AI) was evaluated. PLC/PKC and PKA inhibitors were used to evaluate the signaling pathways downstream from B2R and B1R activation and their effect on TRPA1 sensitization. Anastrozole caused mechanical allodynia and muscle strength loss in mice. B2R (Bradykinin), B1R (DABk), or TRPA1 (AITC) agonists induced overt nociceptive behavior and enhanced and prolonged the painful parameters in anastrozole-treated mice. All painful symptoms were reduced by B2R (Icatibant), B1R (DALBk), or TRPA1 (A967079) antagonists. We observed the interaction between B2R, B1R, and the TRPA1 channel in anastrozole-induced musculoskeletal pain, which was dependent on the activation of the PLC/PKC and PKA signaling pathways. TRPA1 seems to be sensitized by mechanisms dependent on the activation of PLC/PKC, and PKA due to kinin receptors stimulation in anastrozole-treated animals. Thus, regulating this signaling pathway could contribute to alleviating AIs-related pain symptoms, patients’ adherence to therapy, and disease control.

4 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GBGabriela Becker
Gabriela Becker
MFMaria Fernanda Pessano Fialho
Maria Fernanda Pessano Fialho
EBEvelyne Silva Brum
Evelyne Silva Brum
SOSara Marchesan Oliveira
Sara Marchesan Oliveira
Chemotherapy-induced peripheral neuropathy is a severe clinical problem frequently associated with cisplatin use. Although its pathophysiology is poorly understood, it is known that kinin receptors and the transient receptor potential ankyrin 1 (TRPA1) channel play a significant role in the peripheral neuropathy induced by cisplatin in rodents. However, the role of signalling pathways downstream from B2 kinin receptors activation and sensitisation of the TRPA1 channel remains unknown in this model. The cisplatin-induced neuropathy model caused mechanical and cold allodynia in male Swiss mice. Antagonists for kinin B2 and B1 receptors and the TRPA1 channel attenuated the painful parameters. Local sub-nociceptive doses of kinin B2 receptor (bradykinin) and TRPA1 channel (allyl isothiocyanate; AITC) agonists enhanced the painful parameters in cisplatin-treated mice, which their respective antagonists attenuated. Furthermore, we demonstrated the interaction between the kinin B2 receptor and the TRPA1 channel in cisplatin-induced peripheral neuropathy since phospholipase C (PLC) and protein kinase C epsilon (PKCε) inhibitors attenuated the increase in mechanical and cold allodynia evoked by bradykinin and AITC in cisplatin-treated mice. Therefore, regulating the activation of signalling pathways downstream from the kinin B2 receptors activation and TRPA1 channel sensitisation can mitigate the painful peripheral neuropathy decurrent of the oncology treatment with cisplatin.

20 January 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
EBEvelyne Silva Brum
Evelyne Silva Brum
LLLorenzo Landini
Lorenzo Landini
DADaniel Souza Monteiro de Araújo
Daniel Souza Monteiro de Araújo
MMMatilde Marini
Matilde Marini
PGPierangelo Geppetti
Pierangelo Geppetti
SOSara Marchesan Oliveira
Sara Marchesan Oliveira

12 April 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
PSPriscilla Dias Santos
Priscilla Dias Santos
TVThiago Neves Vieira
Thiago Neves Vieira
ACAna Claudia Gontijo Couto
Ana Claudia Gontijo Couto
JLJoão Paulo Mesquita Luiz
João Paulo Mesquita Luiz
ASAndré Luis Lopes Saraiva
André Luis Lopes Saraiva
CSCassia Regina Silva
Cassia Regina Silva

1 September 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SKSabrina Qader Kudsi
Sabrina Qader Kudsi
CACaren Antoniazzi
Caren Antoniazzi
CCCamila Camponogara
Camila Camponogara
EBEvelyne Silva Brum
Evelyne Silva Brum
IBIndiara Brusco
Indiara Brusco
GTGabriela Trevisan
Gabriela Trevisan